PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
IDYA vs. IR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IDYA and IR is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

IDYA vs. IR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IDEAYA Biosciences, Inc. (IDYA) and Ingersoll-Rand Plc (IR). The values are adjusted to include any dividend payments, if applicable.

-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2025February
-43.31%
-3.72%
IDYA
IR

Key characteristics

Sharpe Ratio

IDYA:

-1.14

IR:

-0.11

Sortino Ratio

IDYA:

-1.86

IR:

0.04

Omega Ratio

IDYA:

0.80

IR:

1.01

Calmar Ratio

IDYA:

-0.95

IR:

-0.16

Martin Ratio

IDYA:

-1.79

IR:

-0.39

Ulcer Index

IDYA:

30.04%

IR:

7.44%

Daily Std Dev

IDYA:

47.13%

IR:

27.13%

Max Drawdown

IDYA:

-74.64%

IR:

-49.12%

Current Drawdown

IDYA:

-53.89%

IR:

-17.64%

Fundamentals

Market Cap

IDYA:

$1.81B

IR:

$34.52B

EPS

IDYA:

-$3.36

IR:

$2.06

Total Revenue (TTM)

IDYA:

$7.00M

IR:

$7.24B

Gross Profit (TTM)

IDYA:

-$2.18M

IR:

$3.08B

EBITDA (TTM)

IDYA:

-$182.22M

IR:

$1.79B

Returns By Period

In the year-to-date period, IDYA achieves a -15.45% return, which is significantly lower than IR's -4.08% return.


IDYA

YTD

-15.45%

1M

-6.13%

6M

-43.31%

1Y

-50.94%

5Y*

25.81%

10Y*

N/A

IR

YTD

-4.08%

1M

-7.77%

6M

-3.72%

1Y

-2.36%

5Y*

18.69%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IDYA vs. IR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDYA
The Risk-Adjusted Performance Rank of IDYA is 22
Overall Rank
The Sharpe Ratio Rank of IDYA is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of IDYA is 22
Sortino Ratio Rank
The Omega Ratio Rank of IDYA is 55
Omega Ratio Rank
The Calmar Ratio Rank of IDYA is 11
Calmar Ratio Rank
The Martin Ratio Rank of IDYA is 22
Martin Ratio Rank

IR
The Risk-Adjusted Performance Rank of IR is 3636
Overall Rank
The Sharpe Ratio Rank of IR is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of IR is 3333
Sortino Ratio Rank
The Omega Ratio Rank of IR is 3333
Omega Ratio Rank
The Calmar Ratio Rank of IR is 3737
Calmar Ratio Rank
The Martin Ratio Rank of IR is 3939
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IDYA vs. IR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for IDEAYA Biosciences, Inc. (IDYA) and Ingersoll-Rand Plc (IR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for IDYA, currently valued at -1.14, compared to the broader market-2.000.002.00-1.14-0.11
The chart of Sortino ratio for IDYA, currently valued at -1.86, compared to the broader market-4.00-2.000.002.004.006.00-1.860.04
The chart of Omega ratio for IDYA, currently valued at 0.80, compared to the broader market0.501.001.502.000.801.01
The chart of Calmar ratio for IDYA, currently valued at -0.95, compared to the broader market0.002.004.006.00-0.95-0.16
The chart of Martin ratio for IDYA, currently valued at -1.79, compared to the broader market-10.000.0010.0020.0030.00-1.79-0.39
IDYA
IR

The current IDYA Sharpe Ratio is -1.14, which is lower than the IR Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of IDYA and IR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-1.14
-0.11
IDYA
IR

Dividends

IDYA vs. IR - Dividend Comparison

IDYA has not paid dividends to shareholders, while IR's dividend yield for the trailing twelve months is around 0.09%.


TTM20242023202220212020201920182017
IDYA
IDEAYA Biosciences, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
IR
Ingersoll-Rand Plc
0.09%0.09%0.10%0.15%0.03%2.33%5.78%9.58%3.83%

Drawdowns

IDYA vs. IR - Drawdown Comparison

The maximum IDYA drawdown since its inception was -74.64%, which is greater than IR's maximum drawdown of -49.12%. Use the drawdown chart below to compare losses from any high point for IDYA and IR. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-53.89%
-17.64%
IDYA
IR

Volatility

IDYA vs. IR - Volatility Comparison

IDEAYA Biosciences, Inc. (IDYA) has a higher volatility of 13.54% compared to Ingersoll-Rand Plc (IR) at 9.28%. This indicates that IDYA's price experiences larger fluctuations and is considered to be riskier than IR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%SeptemberOctoberNovemberDecember2025February
13.54%
9.28%
IDYA
IR

Financials

IDYA vs. IR - Financials Comparison

This section allows you to compare key financial metrics between IDEAYA Biosciences, Inc. and Ingersoll-Rand Plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab